CN SAMR Antitrust Guidelines For The Pharmaceutical Sector (Draft For Comments)

Thanks for the notification fromAaron Wininger of Schwegman Lundberg & Woessner, P.A., the China State Administration for Market Regulation SAMR issued Antitrust Guidelines for the Pharmaceutical Sector (draft for comments) on 9 August 2024 at the link below:

https://www.samr.gov.cn/hd/zjdc/art/2024/art_709b7b3bed794e1ca464524d1e5a3dcd.html

The deadline to provide comments for this 30-pages document with 54 articles is 23 August 2024, that is within 14 days from the announcement. (If submission of comments is not desired, I fully understand. As I said many times, if you do not want to listen, just say no and please do not pretend otherwise).

My general feeling is that these guidelines presume that pharmaceutical sellers are by default monopolistic, and whatever you do is just wrong (so why do it at all?). My concerns are with these, pharmaceutical supplies, particularly new ones, may eventually drop in China.